# Takeda ends DNL593 collaboration; Denali regains full rights - Date: 2026-04-06 - Category: Biotech & Life Sciences Takeda terminated its DNL593 partnership for strategic reasons, not safety. Denali regains full rights. The Phase 1/2 trial continues with 40 patients and data due end of 2026. ---